BeiGene Ltd (SHSE:688235)
¥ 133.37 1.74 (1.32%) Market Cap: 134.50 Bil Enterprise Value: 122.01 Bil PE Ratio: 0 PB Ratio: 5.37 GF Score: 55/100

Beigene Ltd Update Call: ASPEN Trial Readout Transcript

Dec 16, 2019 / 01:30PM GMT
Operator

Greetings, and welcome to the BeiGene conference call to discuss the results of the ASPEN clinical trial. (Operator Instructions) As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, BeiGene Chief Financial Officer, Howard Liang, PhD, to start the call. Please go ahead.

Heng Liang
BeiGene, Ltd. - CFO & Chief Strategy Officer

Thank you very much. A warm welcome to all of you joining us from around the globe. On today's call, we'll discuss the results of our head-to-head ASPEN study, which investigated the use of BRUKINSA compared to ibrutinib in Waldenström's patients, and more broadly, provide update on our progress with BRUKINSA development and commercialization.

On today's call, after an introduction by our CEO, John Oyler, our Chief Medical Officer for Hematology, Dr. Jane Huang, will describe the results of the ASPEN study. Jane will be followed by our Chief Advisor, Dr. Eric Hedrick, who will discuss the broader development program for BRUKINSA. Finally, our Head of U.S. Commercial Organization

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot